Monitor for official FDA meeting minutes and any updates on ABO-701 preclinical data. The 2027 IND timeline is unchanged and provides no near-term catalyst. Stock movement likely limited until concrete regulatory milestones are achieved.
Price Chart
Executive Summary
Abeona Therapeutics reported a constructive pre-IND meeting with the FDA regarding ABO-701, a novel T-cell therapy for prostate cancer. The company reaffirms its target to submit an IND application in 2027, but official FDA minutes are pending and no assurance of acceptance was given.
Key Facts
- Pre-IND meeting with FDA held on June 3, 2026 for ABO-701 (PSMA-targeted T-cell therapy for prostate cancer)
- Company believes meeting was constructive; official FDA minutes not yet received
- IND submission target remains 2027, consistent with prior timeline
- No financial figures, deal values, or clinical data disclosed in the filing
Financial Impact
No financial impact disclosed; pre-revenue clinical-stage company with no near-term revenue from ABO-701
Risk Factors
- FDA may require additional preclinical studies or data before accepting IND
- IND may not be accepted or may be delayed beyond 2027
- No assurance of clinical trial authorization or eventual approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027197 |
| Document: 0001493152-26-027197-index-headers.html | 0001493152-26-027197 |
| Document: 0001493152-26-027197-index.html | 0001493152-26-027197 |
| Document: 0001493152-26-027197.txt | 0001493152-26-027197 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access